Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals Stock Forecast

Stock Price Forecast

The 2 analysts that cover Supernus Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $43, which forecasts a -5.43% decrease in the stock price over the next year. The lowest target is $40 and the highest is $46.

Price Target: $43 (-5.43%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$40	$43	$46	$46
Change	-12.03%	-5.43%	+1.17%	+1.17%

Analyst Ratings

The average analyst rating for Supernus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Apr '25	May '25	Jun '25	Jul '25	Aug '25	Sep '25
Strong Buy	0	0	0	0	0	0
Buy	0	0	0	0	1	1
Hold	2	2	2	2	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
David Amsellem Piper Sandler	Piper Sandler	Hold Maintains $36 → $40	Hold	Maintains	$36 → $40	-12.03%	Aug 29, 2025
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $42 → $46	Buy	Maintains	$42 → $46	+1.17%	Aug 6, 2025
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Hold Reiterates $36	Hold	Reiterates	$36	-20.83%	Feb 26, 2025
Kristen Kluska Cantor Fitzgerald	Cantor Fitzgerald	Buy → Hold Downgrades $57 → $36	Buy → Hold	Downgrades	$57 → $36	-20.83%	Feb 19, 2025
David Amsellem Piper Sandler	Piper Sandler	Buy → Hold Downgrades $41 → $36	Buy → Hold	Downgrades	$41 → $36	-20.83%	Sep 11, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

693.88M

Increased by 4.84%

from 661.82M

Revenue Next Year

816.65M

Increased by 17.69%

from 693.88M

EPS This Year

2.16

Increased by 63.82%

from 1.32

EPS Next Year

2.22

Increased by 2.59%

from 2.16

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	520.40M	579.78M	667.24M	607.52M	661.82M	693.88M	816.65M
Revenue Growth	32.50%	11.41%	15.09%	-8.95%	8.94%	4.84%	17.69%
EPS	2.36	0.98	1.04	0.02	1.32	2.16	2.22
EPS Growth	12.38%	-58.48%	6.32%	-98.08%	6,500.00%	63.82%	2.59%
Forward PE	-	-	-	-	-	21.03	20.50
No. Analysts	-	-	-	-	-	7	7

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	732.9M	886.0M
Avg	693.9M	816.7M
Low	627.5M	692.4M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	10.7%	27.7%
Avg	4.8%	17.7%
Low	-5.2%	-0.2%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	2.31	2.31
Avg	2.16	2.22
Low	2.00	2.11

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	75.0%	6.8%
Avg	63.8%	2.6%
Low	51.5%	-2.6%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.